SCHEMBL4056950

SCHEMBL4056950

COc1ccc(Cc2nc3ncc(-c4ccc(C#N)cc4)cc3[nH]2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 4/20 0.52
GRIN2B Q13224 4/20 0.52
AURKA O14965 1/20 0.49
NOS3 P29474 1/20 0.48
NOS1 P29475 1/20 0.48
NOS2 P35228 1/20 0.48
USP30 Q70CQ3 3/20 0.44
CNR1 P21554 1/20 0.43
IKBKE Q14164 4/20 0.42
TBK1 Q9UHD2 4/20 0.42
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
AURKB Q96GD4 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
MAPK14 Q16539 1/20 0.42
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4052457 0.85 NOS3 (0.63) GRIN1GRIN2BAURKANOS3NOS1
SCHEMBL4063445 0.83 AURKA (0.69) GRIN1GRIN2BAURKAUSP30IKBKE
SCHEMBL13607942 0.83 GRIN1 (0.56) GRIN1GRIN2BCNR1LMNAHTT
SCHEMBL4053597 0.82 PTGS2 (0.49) AURKANOS3NOS1NOS2IKBKE
SCHEMBL4051416 0.81 NOS3 (0.55) GRIN1GRIN2BAURKANOS3NOS1
SCHEMBL4061118 0.77 SMN1; SMN2 (0.63) GRIN1GRIN2BAURKANOS3NOS1
SCHEMBL4057348 0.77 NOS3 (0.48) GRIN1GRIN2BAURKANOS3NOS1
SCHEMBL4051128 0.77 NOS3 (0.48) GRIN1GRIN2BAURKANOS3NOS1
SCHEMBL4058742 0.76 GRIN1 (0.55) GRIN1GRIN2BAURKANOS3NOS1
SCHEMBL4050460 0.76 NOS3 (0.49) GRIN1GRIN2BAURKANOS3NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B GRIN1 3175/4885GRIN2B 1116/4885AURKA 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.